Med. praxi. 2015;12(4):189-191

Current treatment options for erectile dysfunction and premature ejaculation

MUDr.Kateřina ©rámková
Urologické oddělení Fakultní nemocnice u sv. Anny v Brně

Erectile dysfunction and premature ejaculation are disorders, they affect physical and psychosocial health and have a significant impact

on the QOL of sufferers and their partners. Three lines erectile dysfunction therapy include oral therapy, vacuum constriction device,

intracavernous therapy, penile prosthesis and novel shock wave therapy. Current oral form of erectile dysfunction therapy by PDE5

inhibitors is safe and effective and is well tolerated. The modern premature ejaculation therapy is an oral treatment with dapoxetine.

Dapoxetine significantly prolonged intravaginal ejaculatory latency time compared with placebo, increases the control of ejaculation,

reduces stress and interpersonal difficulties, increases satisfaction.

Keywords: erectile dysfunction, premature ejaculation, treatment, PDE5-inhibitors, dapoxetine

Published: September 19, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©rámková K. Current treatment options for erectile dysfunction and premature ejaculation. Med. praxi. 2015;12(4):189-191.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Symonds T, Roblin D, Hart K, et al. How does premature ejaculation impact a man's life. Journal of Sex & Marital Therapy 2003; 29: 361-370. Go to original source... Go to PubMed...
    2. Hatzimouratidis K, Eardley I, Giuliano F, et al. Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation 2015 http://www.uroweb.org/ http://www.uroweb.org/gls/pdf/14_Male%20Sexual%20Dysfunction_LR.pdf.
    3. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61. Go to original source... Go to PubMed...
    4. ©rámková T. Sexuologie pro zdravotníky. Galén, Praha 2015. ISBN 978-80-7492-162-9, 237 stran.
    5. Rosen RC, Riley A, Wagner G, et al. The International Index of Eectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology, 1997; 49(6): 822-830. Go to original source... Go to PubMed...
    6. Goldstein I, Mulhall JP, Bushmakin AG, et al. The Erection Hardness Score and its relationship to successful sexual intercourse. J Sex Med 2008; 5: 2374-2380. Go to original source... Go to PubMed...
    7. European Medicine Agency: Viagra (sildenafil) http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000202/WC500049830.pdf.
    8. European Medicine Agency: Cialis (tadalafil) http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000436/WC500026318.pdf.
    9. Giuliano F, Mirone V, Xu L, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international randomised, parallel, placebo-controlled clinical trials. Euro Urol 2012; 61: 917-925. Go to original source...
    10. European Medicine Agency: Levitra (vardenafil).
    11. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000475/WC500039992.pdf.
    12. European Medicine Agency: Spedra (avanafil) http://ec.europa.eu/health/documents/community - register/2013/20130621126046/anx_126046_cs.pdf.
    13. Breza J. Erektilné poruchy. 1. vydání, Osveta Martin 1994: 270.
    14. Gruenvald I, Kitrey ND, Appel B. Low-intensity extracorporeal shock wave therapy in vascular disease and erectile dysfunction: theory and outcomes. Sex Med Rev, 2013; 1: 83-90. Go to original source...
    15. Linet OI. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334(14): 873-877. Go to original source...
    16. Trost L, Hellstrom WJG. History, contemporary outcomes, and future of penile prostheses: A review of the literature. Sex Med Rev 2013; 1: 150-163. Go to original source... Go to PubMed...
    17. Janini EA, Lenzi A. Epidemiology of premature ejaculation. Curr. Opin. Urol. 2005; 15: 399-403. Go to original source... Go to PubMed...
    18. Janini EA, Carosa M, Pepe F, et al. Update of pathophysiology of premature ejaculation: the bases for new pharmacological treatments. EAU-EBU Updates Series 2006; 4: 141-149. Go to original source...
    19. Waldinger MD, Rietschel M, Nothen MM, Hengeveld MW, Olivier et al. Familial occurrence of primary premature ejaculation. Psychiatr Genet 1998; 8: 37-40. Go to original source... Go to PubMed...
    20. Screponi E, Carosa E, Di Stasi SM, et al. Prevalence of chronic prostatitis in men with premature ejaculation. Urology 2001; 58(2): 198-202. Go to original source... Go to PubMed...
    21. Carani C, Isidori AM, Granata, E et al. Multicenter study on the prevalence of sexual symptoms in male hypo - and hyperthyroid patients. J. Clin. Endocrinol. Metab 2005; 90: 6472-6479. Go to original source...
    22. Janini EA, Lombardo F, Lenzi A. Correlation between ejaculatory and erectile dysfunction. Int J Androl 2005; 28(Suppl. 2): 40-45. Go to original source...
    23. Montague DK, Jarow J, Broderick GA, et al. AUA Guidelines on the pharmacologic management of premature ejaculation. Journal of Urology 2014; 172, July: 290-294. DOI:10.1097/01.ju.0000132159.61156.ea. Go to original source...
    24. European Medicine Agency. Dapoxetine (Priligy) http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Priligy_29/WC500124576.pdf.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.